Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous tre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2012-05, Vol.13 (5), p.528-538
Hauptverfasser:	Miller, Vincent A, Prof, Hirsh, Vera, MD, Cadranel, Jacques, Prof, Chen, Yuh-Min, MD, Park, Keunchil, Prof, Kim, Sang-We, Prof, Zhou, Caicun, Prof, Su, Wu-Chou, Prof, Wang, Mengzhao, Prof, Sun, Yan, Prof, Heo, Dae Seog, Prof, Crino, Lucio, Prof, Tan, Eng-Huat, MD, Chao, Tsu-Yi, Prof, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, James Chih-Hsin, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Acne Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Chemotherapy Diarrhea Double-Blind Method Drug dosages Erlotinib Hydrochloride Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - secondary Male Middle Aged Mutation Oncology Patients Protein Kinase Inhibitors - therapeutic use Quinazolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!